|

CAR-T cells Clinical Trials

9 actively recruiting trials

▲ +1 trial since June 2026

Also known as: CAR-T cells injection

Pipeline

Early 1: 1Phase 1: 4Phase 2: 1Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Shenzhen Geno-Immune Medical Institute2
  • Zhejiang University1
  • Tongji Hospital1
  • Suzhou Immunofoco Biotechnology Co., Ltd1
  • Second Affiliated Hospital of Guangzhou Medical University1

Indications

  • Cancer9
  • B-Cell Non-Hodgkin Lymphoma3
  • Multiple Myeloma2
  • Mesothelin1
  • Relapsed/Refractory B-cell Non-Hodgkin Lymphoma1

Other9 trials

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
Phase 1
A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
Phase 1
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Phase 3
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
Early 1
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Phase 1/2
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Phase 1
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Phase 1/2
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.